https://seekingalpha.com/article/4752497-erasca-future-streamlined-but-still-uncertain [Seeking Alpha]
Erasca, Inc. (ERAS)
Company Research
Source: Seeking Alpha
The company has $460 million in cash and marketable securities, sufficient to fund activities into H1 2027, with no long-term debt. Its lead candidate is targeting NRASm melanoma, which affects some 70,000 patients on a global basis annually. It is now in Phase 3 development. An updated analysis around Erasca, Inc. follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » ipopba Today, we put Erasca, Inc. ( NASDAQ: ERAS in the spotlight. It is my first look at this clinical stage biotech concern since an article that was posted on this small-cap company in July 2023. The company restructured its Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-tim
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Platform Technologies Drive $211B Surge in Precision Cancer TreatmentPR Newswire
- Erasca (NASDAQ:ERAS) was given a new $5.00 price target on by analysts at Mizuho.MarketBeat
- Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results [Yahoo! Finance]Yahoo! Finance
- Erasca to Present at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Erasca to Present at the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 12/15/25 - Form 144
- 11/17/25 - Form 144
- 11/14/25 - Form SCHEDULE
- ERAS's page on the SEC website